Details of the Drug

General Information of Drug (ID: DMQ2JO5)

Drug Name
Hydrocodone
Synonyms
HYDROCODONE; Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193; Bekadid; Hidrocodona; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 299.4
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
10.2% of drug is excreted from urine in the unchanged form [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.1474 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 62.5 mg/mL [3]
Chemical Identifiers
Formula
C18H21NO3
IUPAC Name
(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Canonical SMILES
CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
InChIKey
LLPOLZWFYMWNKH-CMKMFDCUSA-N
Cross-matching ID
PubChem CID
5284569
ChEBI ID
CHEBI:5779
CAS Number
125-29-1
DrugBank ID
DB00956
TTD ID
D0X5KF
ACDINA ID
D00313

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [6], [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hydrocodone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Hydrocodone and Oxymorphone. Pain [MG30-MG3Z] [18]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Hydrocodone and Dezocine. Pain [MG30-MG3Z] [19]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Hydrocodone and Flavoxate. Pain [MG30-MG3Z] [20]
Coadministration of a Drug Treating the Disease Different from Hydrocodone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Hydrocodone caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [21]
Ivosidenib DM8S6T7 Major Increased metabolism of Hydrocodone caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Arn-509 DMT81LZ Major Increased metabolism of Hydrocodone caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Hydrocodone and Oliceridine. Acute pain [MG31] [18]
Emapalumab DMZG5WL Moderate Altered metabolism of Hydrocodone due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [23]
Siltuximab DMGEATB Moderate Altered metabolism of Hydrocodone due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [23]
Dronedarone DMA8FS5 Major Decreased metabolism of Hydrocodone caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [24]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Hydrocodone and Chlormezanone. Anxiety disorder [6B00-6B0Z] [18]
Posaconazole DMUL5EW Major Decreased metabolism of Hydrocodone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [24]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Hydrocodone and Desipramine. Attention deficit hyperactivity disorder [6A05] [25]
Oritavancin DM28D05 Moderate Increased metabolism of Hydrocodone caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Dalfopristin DM4LTKV Major Decreased metabolism of Hydrocodone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Clarithromycin DM4M1SG Major Decreased metabolism of Hydrocodone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Troleandomycin DMUZNIG Major Decreased metabolism of Hydrocodone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Telithromycin DMZ4P3A Major Decreased metabolism of Hydrocodone caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Hydrocodone and Cariprazine. Bipolar disorder [6A60] [18]
Erdafitinib DMI782S Moderate Increased metabolism of Hydrocodone caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [26]
Tucatinib DMBESUA Major Decreased metabolism of Hydrocodone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Hydrocodone and Levomilnacipran. Chronic pain [MG30] [25]
Lumacaftor DMCLWDJ Major Increased metabolism of Hydrocodone caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [27]
MK-8228 DMOB58Q Major Decreased metabolism of Hydrocodone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [24]
Sertraline DM0FB1J Moderate Additive serotonergic effects by the combination of Hydrocodone and Sertraline. Depression [6A70-6A7Z] [25]
Vilazodone DM4LECQ Moderate Additive serotonergic effects by the combination of Hydrocodone and Vilazodone. Depression [6A70-6A7Z] [25]
Nefazodone DM4ZS8M Major Decreased metabolism of Hydrocodone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [24]
Vortioxetine DM6F1PU Moderate Additive serotonergic effects by the combination of Hydrocodone and Vortioxetine. Depression [6A70-6A7Z] [25]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Hydrocodone and Milnacipran. Depression [6A70-6A7Z] [25]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Hydrocodone and Escitalopram. Depression [6A70-6A7Z] [25]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Hydrocodone and Desvenlafaxine. Depression [6A70-6A7Z] [25]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Hydrocodone and OPC-34712. Depression [6A70-6A7Z] [18]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Hydrocodone and Clomipramine. Depression [6A70-6A7Z] [25]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Hydrocodone and Doxepin. Depression [6A70-6A7Z] [25]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Hydrocodone and Esketamine. Depression [6A70-6A7Z] [28]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Hydrocodone and Mepenzolate. Digestive system disease [DE2Z] [29]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive serotonergic effects by the combination of Hydrocodone and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [25]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Hydrocodone and Oxybutynine. Discovery agent [N.A.] [29]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Hydrocodone and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [30]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Hydrocodone and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [31]
Cenobamate DMGOVHA Major Increased metabolism of Hydrocodone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Stiripentol DMMSDOY Major Decreased metabolism of Hydrocodone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Fosphenytoin DMOX3LB Major Increased metabolism of Hydrocodone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Hydrocodone and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [18]
Rufinamide DMWE60C Moderate Increased metabolism of Hydrocodone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Phenobarbital DMXZOCG Major Increased metabolism of Hydrocodone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Eslicarbazepine DMZREFQ Major Increased metabolism of Hydrocodone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Hydrocodone and Dantrolene. Fever [MG26] [18]
Tazemetostat DMWP1BH Moderate Increased metabolism of Hydrocodone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [21]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Hydrocodone and Solifenacin. Functional bladder disorder [GC50] [29]
Itraconazole DMCR1MV Major Decreased metabolism of Hydrocodone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [24]
Miconazole DMPMYE8 Moderate Decreased metabolism of Hydrocodone caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [33]
Ketoconazole DMPZI3Q Major Decreased metabolism of Hydrocodone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [24]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Hydrocodone caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [21]
Boceprevir DMBSHMF Major Decreased metabolism of Hydrocodone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [24]
Telaprevir DMMRV29 Major Decreased metabolism of Hydrocodone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [24]
Rifampin DMA8J1G Major Increased metabolism of Hydrocodone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [27]
Rifapentine DMCHV4I Major Increased metabolism of Hydrocodone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Hydrocodone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Cobicistat DM6L4H2 Major Decreased metabolism of Hydrocodone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Saquinavir DMG814N Major Decreased metabolism of Hydrocodone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Etravirine DMGV8QU Major Increased metabolism of Hydrocodone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Darunavir DMN3GCH Major Decreased metabolism of Hydrocodone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Atazanavir DMSYRBX Major Decreased metabolism of Hydrocodone caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Lesinurad DMUR64T Moderate Increased metabolism of Hydrocodone caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [21]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Hydrocodone and Belladonna. Infectious gastroenteritis/colitis [1A40] [20]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Hydrocodone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [34]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Hydrocodone and Suvorexant. Insomnia [7A00-7A0Z] [18]
Amobarbital DM0GQ8N Major Increased metabolism of Hydrocodone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [32]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Hydrocodone and Ramelteon. Insomnia [7A00-7A0Z] [18]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Hydrocodone and Zaleplon. Insomnia [7A00-7A0Z] [18]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Hydrocodone and Tasimelteon. Insomnia [7A00-7A0Z] [18]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Hydrocodone and Paraldehyde. Insomnia [7A00-7A0Z] [18]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Hydrocodone and ITI-007. Insomnia [7A00-7A0Z] [18]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Hydrocodone and Quazepam. Insomnia [7A00-7A0Z] [18]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Hydrocodone and Estazolam. Insomnia [7A00-7A0Z] [18]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Hydrocodone and Polyethylene glycol. Irritable bowel syndrome [DD91] [35]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Hydrocodone and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [18]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Hydrocodone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [23]
Crizotinib DM4F29C Major Decreased metabolism of Hydrocodone caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [24]
Brigatinib DM7W94S Moderate Increased metabolism of Hydrocodone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [21]
Ceritinib DMB920Z Major Decreased metabolism of Hydrocodone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [24]
PF-06463922 DMKM7EW Major Increased metabolism of Hydrocodone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [22]
Selpercatinib DMZR15V Moderate Decreased metabolism of Hydrocodone caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [23]
Idelalisib DM602WT Major Decreased metabolism of Hydrocodone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [24]
IPI-145 DMWA24P Major Decreased metabolism of Hydrocodone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [24]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Hydrocodone caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [36]
Vemurafenib DM62UG5 Moderate Increased metabolism of Hydrocodone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [21]
LGX818 DMNQXV8 Moderate Increased metabolism of Hydrocodone caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [37]
Dabrafenib DMX6OE3 Major Increased metabolism of Hydrocodone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [22]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Hydrocodone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [38]
Frovatriptan DM7RE8P Moderate Additive CNS depression effects by the combination of Hydrocodone and Frovatriptan. Migraine [8A80] [25]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Hydrocodone and Lasmiditan. Migraine [8A80] [39]
Exjade DMHPRWG Moderate Increased metabolism of Hydrocodone caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [21]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Hydrocodone and Thalidomide. Multiple myeloma [2A83] [40]
Fedratinib DM4ZBK6 Major Decreased metabolism of Hydrocodone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [24]
Prasugrel DM7MT6E Moderate Altered absorption of Hydrocodone due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [41]
Netupitant DMEKAYI Major Decreased metabolism of Hydrocodone caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [24]
Entrectinib DMMPTLH Moderate Decreased metabolism of Hydrocodone caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [42]
Sibutramine DMFJTDI Moderate Additive serotonergic effects by the combination of Hydrocodone and Sibutramine. Obesity [5B80-5B81] [25]
Dexfenfluramine DMJ7YDS Moderate Additive serotonergic effects by the combination of Hydrocodone and Dexfenfluramine. Obesity [5B80-5B81] [25]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Hydrocodone and Levomethadyl Acetate. Opioid use disorder [6C43] [30]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Hydrocodone and Apraclonidine. Optic nerve disorder [9C40] [43]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Hydrocodone and Pimavanserin. Parkinsonism [8A00] [18]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Hydrocodone and Orphenadrine. Parkinsonism [8A00] [18]
Abametapir DM2RX0I Moderate Decreased metabolism of Hydrocodone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [44]
Lefamulin DME6G97 Moderate Decreased metabolism of Hydrocodone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [45]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Hydrocodone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [24]
ABIRATERONE DM8V75C Major Decreased metabolism of Hydrocodone caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [24]
Enzalutamide DMGL19D Major Increased metabolism of Hydrocodone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [22]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Hydrocodone due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [23]
Ixekizumab DMXW92T Moderate Altered metabolism of Hydrocodone due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [23]
Tocilizumab DM7J6OR Moderate Altered metabolism of Hydrocodone due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [23]
Canakinumab DM8HLO5 Moderate Altered metabolism of Hydrocodone due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [23]
Rilonacept DMGLUQS Moderate Altered metabolism of Hydrocodone due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [23]
Golimumab DMHZV7X Moderate Altered metabolism of Hydrocodone due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [23]
Dexamethasone DMMWZET Major Increased metabolism of Hydrocodone caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [22]
Sarilumab DMOGNXY Moderate Altered metabolism of Hydrocodone due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [23]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Hydrocodone and Quetiapine. Schizophrenia [6A20] [46]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Hydrocodone and Aripiprazole. Schizophrenia [6A20] [18]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Hydrocodone and Iloperidone. Schizophrenia [6A20] [18]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Hydrocodone and Molindone. Schizophrenia [6A20] [18]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Hydrocodone and Thiothixene. Schizophrenia [6A20] [46]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Hydrocodone and Asenapine. Schizophrenia [6A20] [18]
Voxelotor DMCS6M5 Major Decreased metabolism of Hydrocodone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [24]
Telotristat ethyl DMDIYFZ Major Increased metabolism of Hydrocodone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [27]
Armodafinil DMGB035 Major Increased metabolism of Hydrocodone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [22]
LEE011 DMMX75K Major Decreased metabolism of Hydrocodone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Brilinta DMBR01X Moderate Altered absorption of Hydrocodone due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [41]
Elagolix DMB2C0E Major Increased metabolism of Hydrocodone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [22]
Amiodarone DMUTEX3 Major Decreased metabolism of Hydrocodone caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [24]
⏷ Show the Full List of 128 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
Caprylic acid E00017 379 Emulsifying agent; Flavoring agent; Surfactant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Hydrocodone 20 mg tablet 20 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 100 mg tablet 100 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 40 mg tablet 40 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 60 mg tablet 60 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 30 mg tablet 30 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 80 mg tablet 80 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 120 mg tablet 120 mg Abuse-Deterrent 24 HR Extended Release Oral Tablet Oral
Hydrocodone 10 mg capsule 10 mg 12 HR Extended Release Oral Capsule Oral
Hydrocodone 15 mg capsule 15 mg 12 HR Extended Release Oral Capsule Oral
Hydrocodone 20 mg capsule 20 mg 12 HR Extended Release Oral Capsule Oral
Hydrocodone 30 mg capsule 30 mg 12 HR Extended Release Oral Capsule Oral
Hydrocodone 40 mg capsule 40 mg 12 HR Extended Release Oral Capsule Oral
Hydrocodone 50 mg capsule 50 mg 12 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7081).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 088017.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Clinical pipeline report, company report or official report of kempharm.
7 The Relative Abuse Liability of Oral Oxycodone, Hydrocodone and Hydromorphone Assessed in Prescription Opioid Abusers
8 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
9 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
10 Clinical pipeline report, company report or official report of signaturerx.
11 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
12 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
13 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
14 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
15 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
16 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
18 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
19 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
20 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
21 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
22 Canadian Pharmacists Association.
23 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
25 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
26 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
27 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
28 Cerner Multum, Inc. "Australian Product Information.".
29 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
30 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
31 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
32 Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
33 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
34 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
35 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
36 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
37 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
38 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
39 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
41 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
42 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
43 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
44 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
45 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
46 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.